Clinical Trial Update: Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating 6 months of paricalcitol injections or oral therapy for secondary hyperparathyroidism in dialysis patients; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperparathyroidism

Drugs mentioned

• Zemplar (paricalcitol) (paricalcitol)

Snippet

Sponsor: Abbott | Conditions: Secondary Hyperparathyroidism, Dialysis | Phase 4 | Status: COMPLETED | Results posted: 2011-10-25